US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
12 juin 2019 07h00 HE
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
07 mai 2018 21h43 HE
|
Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...